Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use

Drugs

Volumn 55, Issue 3, 1998, Pages 383-404

  Moyle, Graeme J ^a   Gazzard, Brian C ^a   Cooper, David A ^b   Gatell, José ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ST VINCENT S HOSPITAL   (Australia)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; FLUCONAZOLE; GANCICLOVIR; HYDROXYUREA; INDINAVIR; ISONIAZID; LAMIVUDINE; NAPROXEN; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PHENYTOIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THEOPHYLLINE; UNCLASSIFIED DRUG; VINCA ALKALOID; ZALCITABINE; ZIDOVUDINE;

ALOPECIA; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; DIABETES MELLITUS; DRUG CHOICE; DRUG PENETRATION; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG USE; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MEDICAL DECISION MAKING; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROLITHIASIS; PANCREAS DISEASE; PERIPHERAL NEUROPATHY; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE; VERTIGO; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES; VINCA;

EID: 0031937159     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855030-00005     Document Type: Review

References (170)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22
2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6
3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300
4. Emini EA, Holder DJ, Shivaprakash M, et al. The sustained suppression of circulating HIV-1 in indinavir-treated patients is a consequence of the complete prevention of new viral infection cycles. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
5. Kempf D, Rode R, Xu Y, et al. The durability of response to protease inhibitor therapy is predicted by viral load [abstract no. 62]. International Workshop on HIV Drug Resistance. Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
6. Luizzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996; 10: F51-6
7. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996; 174: 1200-6
8. Deeks S, Grant R, Horton C, et al. Virologic effect of ritonavir (RTV) plus saquinavir (SQV) in subjects who have failed indinavir (IDV). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto
9. Mohri H, Singh MK, Ching WTW, et al. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993; 90: 25-9
10. Nàjera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1494; 10: 1479-88
11. Nàjera I, Holguin A, Quinones-Mateu E, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995; 69: 23-31
12. Frost SDW, McLean AR. Quasispecies dynamics and the emergence of drug resistance during zidovudine theraphy of HIV infection. AIDS 1994; 8: 323-32
13. Kellam P, Boucher CAB, Tijnagal JMGH, et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994; 75: 341-51
14. Decks S, Loftus R, Cohen P, et al. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto
15. Conway B. The activity and safety of two formulations of saquinavir combined with two nucleosides in treatment-naïve patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
16. BHIVA Guidelines co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-92
17. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962-9
18. DeMasi R, Staszewski S, Dawson D, et al. Control of HIV-1 RNA prevents clinical disease progression to AIDS [abstract no. 105]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
19. Fischl MA, Richman DD, Greico MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185-91
20. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727-37
21. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection - a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9
22. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment wilh zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437-43
23. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infeelion and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297-303
24. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deterred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81
25. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738-43
26. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994; 272: 437-42
27. Noticeboard: didanosine and ACTG 116A [editorial]. Lancet 1993; 341: 109
28. Follansbee S, Drew L, Olsen R, et al. The efficacy of zalcitahine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naïve patients with advanced HIV disease: a randomized, double-blind comparative trial (ACTG 114; N3300) [abstract no. PO-B26-2113]. IXth International Conference on AIDS and 4th World Congress on STD; 1993 Jun 7-11: Berlin
29. Hammer S, Katzenstein D, Hughes, M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90
30. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-8
31. Massari F, Staszewski S, Berry P, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs zidovudine alone in zidovudine naïve patients [abstract no. LB-6]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20: San Francisco
32. Massari F, Conant M, Mellors J. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine, and didanosine versus indinavir alone and zidovudine/ didanosine in antiretroviral naïve patients [abstract no. 90]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28: Washington, D.C.
33. Danner SA, Carr A, Leonard JM, et al. Safety, pharmacokinetics and antiviral activity of ritonavir, an inhibitor of HIV-1 protease [abstract no. 75]. 4th International Workshop on HIV Drug Resistance; 1995 Jul 6-9: Sardinia, Italy
34. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33
35. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 infection. N Engl J Med 1995; 333: 1534-9
36. Molla A, Korneyeva M, Gao Q. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2: 760-6
37. Norbeck D, Hsu A, Granneman R, et al. Virologic and immunologic response to ritonavir (ABT-538), an inhibitor of HIV protease [abstract no. 70]. 4th International Workshop on HIV Drug Resistance; 1995 Jul 6-9; Sardinia, Italy
38. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor Ag 1343 [abstract no. LB-4]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-29: San Francisco
39. Moyle G, Youle M, Chapman S, et al. A Phase II dose-escalation study of the Agouron protease inhibitor Ag 1343 [abstract no. LB-3]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20: San Francisco
40. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4: pl T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039-50
41. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91
42. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21
43. Hammer SM, Hughes MD, Squires K, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
44. Loveday C, Devereux H, Burke A, et al. A comparison of HIV-1 RNA load assays for baseline values prior to commencing therapy in a clinic population with epidemiological evidence of non-clade B virus [abstract no. 45]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petershurg (FL)
45. Opravil M, DeMasi R, Hill A. Prediction of long-term HIV RNA suppression during zidovudine/lamivudine treatment [abstract no. 60]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
46. Borleffs JCC, Boucher CAB, Schuurman R, et al. Saquinavir-soft gelatin capsules versus indinavir as part of AZT and 3TC containing triple therapy. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
47. Posniak A. Study of protease inhibitors in combination in Europe (SPICE). 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
48. Murphy R, Pottage J, Peterson D, et al. A 15-site, open-label, randomized, comparative study of stavudine + didanosine + indinavir versus zidovudine + lamivudine + indinavir in treatment naive HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
49. Gulick R, Santana J, Squires K, et al. A 15-site, open-label, randomized, comparative study of stavudine + lamivudine + indinavir versus zidovudine + lamivudine + indinavir in treatment naive HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
50. Moyle GJ, Gazzard BG. The role of stavudine in the management of adults with HIV infection. Antiviral Ther 1997; 2: 207-18
51. Conway B, Montaner JSG, Cooper D, et al. Randomised double blind one year study of the immunological and virological effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naïve, AIDS-free patients with CD4 200-600 [abstract no. OP7.2]. AIDS 1996; 10 Suppl. 2: S15
52. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5: 1183-99
53. Hicks C, Hass D, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safely of DMP 266 (Efavirenz, Sustiva) in combination with open label zidovudine (ZDV) with lamivudine [abstract no. 920]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
54. Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine, and zalcitabine triple therapy. Antiviral Ther 1997; 2: 175-83
55. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate) in triple combination therapy. Infectious Diseases Society of America Annual Meeting; 1997 Sep 13-16: San Francisco
56. Cameron DW, Heath-Chiozzi M, Kravcik S. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract no. Mo.B.411]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
57. Heath-Chiozzi M, Leonard J, Sun E, et al. Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness [abstract no. We.B.3127]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
58. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
59. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults w ith human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
60. Mayers D, Riddler S, Bach M, et al. Durable clinical activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks [abstract no. I-175]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sep 28-Oct 1: Toronto
61. Pedneault L, Elion R, Adler M, et al. Stavudine, didanosine, and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
62. 2. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
63. Harris M, Rachlis A, Shillington A, et al. Long-term suppression of HIV in plasma w ith a combination of two nucleosides and nevirapine (NVP). 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
64. Pakker N, Kroon E, Hall D, et al. Functional capacity of T cells and immunological response in naïve HIV-1 patients treated with combinations of reverse transcriptase inhibitors [abstract no. OP2.1]. AIDS 1996; 10 Suppl. 2: S10
65. Ruiz NM, Manion DJ, Labriola DF, et al. HIV-1 suppression to '<1 copy/mL' by Amplicor assay in patients receiving indinavir +/- DMP 266 (efavirenz): results of DMP 266-003, cohort IV [abstract no. 921]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
66. Gao WY, Johns DG, Mitsuya H. Anti-HIV-1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994; 46: 767-72
67. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1995; 10: 36-40
68. Montaner JSG, Zala C, Raboud JM, et al. A pilot study of hydroxyurea (HO-urea) as adjuvant therapy among patients with advanced HIV disease receiving didanosine (ddI) therapy [abstract no. 406]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28; Washington, DC
69. Molla A, Korneyeva M, Chernyavskiy T, et al. Characterization of HIV-1 protease mutations, compliance and drug concentrations in patients who have HIV RNA rebound on ritonavir/saquinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
70. Bodsworth NJ, Heaps M, Gosling D, et al. Efficacy of indinavir (IDV) and ritonavir (RTV) in patients pretreated with saquinavir [abstract]. 7th International Antiviral Symposium; 1997 Feb 17-19: Sydney
71. Novak RM, Colombo J, Linares-Diaz M, et al. Comparison of AZT/3TC VS. D4T/3TC for the treatment of HIV in persons with CD4 counts <300 and prior AZT experience [abstract no. Tu.B. 2132]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
72. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-7
73. Holodniy M, Katzentein D, Mole L, et al. Human immunodeficiency virus reverse transcriptase Codon 215 mutations dimmish virologic response to didanosine-/idovudine therapy in subjects with non-syncytium-inducing viral phenotype. J Infect Dis 1996; 174: 854-7
74. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcilabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32
75. Abrams DI, Goldman A, Launer C, et al. A comparative trial of didanosine or zidovudine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657-62
76. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997; 126: 355-63
77. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995; 171: 1172-9
78. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir and zalcitabine [abstract no. LB.H. 6033]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
79. Davey RT, Chain DG, Reed GF, et al. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected patients. Antimicrob Agents Chemother 1996; 40: 1657-64
80. Sylvester S, Caliendo A, An D, et al. HIV-1 resistance mutations and plasma RNA during ZDV+ddC combination therapy [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 23
81. Schooley RT, Ramirez-Ronda C, Lange JMA. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173: 1354-66
82. Quinones-Mateu ME. A unique mechanism for zidovudine-resistance and evidence for a zidovudine-mediated cross-resistance to other nucleoside analogues by zidovudine-resistant viruses [abstract no. 10]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
83. Kleim JP, Pauosner M, Winkler I, et al. Nucleoside reverse transcriptase inhibitor-specific mutations within the HIV-1 pol gene selected with a non-nucleoside type RT inhibitor [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 2
84. Shirasaka T, Kavlick MF, Veno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402
85. Para MF, Collier A, Coombs R, et al. ACTG 333: antiviral effects of switching from saquinavir hard capsules (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs switching to indinavir (IDV) after prior saquinavir [abstract no. 299]. Infectious Diseases Society of America Annual Meeting; 13-16 Sep 1997: San Francisco
86. Schapiro J, Winters M, Lawrence J, et al. Clinical and genotypic cross-resistance between the protease inhibitors saquinavir and indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28; St Petersburg (FL)
87. Dulioust A, Paulous S, Guillemot L, et al. Selection of saquinavir-resistant mutants by indinavir following a switch from saquinavir [abstract no. 16]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
88. Lawrence J, Schapiro J, Pesano R, et al. Clinical response and genolypic resistance patterns of sequential therapy with nelfinavir followed by indinavir plus nevirapine in saquinavir/reverse transcriptase inhibitor-experienced patients [abstract no. 64]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg
89. Pym AS, Churchill DR, Galpin S, et al. Presence of mutation at codon 90 may predict response to ritonavir/saquinavir combination in HIV seropositive patients pretreated with saquinavir monotherapy [abstract no. 84]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
90. Walmsley S, Clark J, Salti I, et al. Can protease inhibitors be used sequentially in patients with advanced HIV infection [abstract no. I-189]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 28 Sep-1 Oct 1997: Toronto
91. Miller V, Hertogs K, de Bethune M-P, et al. Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: impact on subsequent ritonavir/saquinavir combination therapy [abstract no. 81]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28: St Petersburg (FL)
92. Alpha International Coordinating Committee. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine intolerant patients with symptomatic HIV disease. AIDS 1996; 10 (8): 867-80
93. Allan JD, De Gruttola V, Cross A, et al. An efficacy study of 23-dideoxyinosine (ddI) (BMY-40900) administered orally twice daily to zidovudine intolerant patients with HIV infections (ACTG 118) [abstract no. WS-B24-2]. IXth International Conference on AIDS and 4th World Congress on STD; 7-11 June 1993: Berlin
94. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine (ddI) in HIV antibody positive individuals intolerant to zidovudine (AZT). Q J Med 1993; 86: 155-63
95. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657-62
96. Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access Programme. Int J Antimicrob Agents 1996; 7: 41-8
97. Farthing C, Japour A, Cohen C, et al. Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with ritonavir (RIT)-saquinavir (SQV) in protease inhibitor naïve patients [abstract no. LB3]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sep-1 Oct 1997: Toronto
98. Cohen C, Sun E, Cameron D, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients [abstract no. LB7b]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 15-18 Sep 1996: New Orleans
99. Gazzard BG, Moyle GJ. Individualisation of HIV therapy: the clinician's perspective. Br J Clin Prac 1995; 49: 145-7
100. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-31
101. Keilbaugh SA, Prusoff WH, Simpson MV. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV 1-dideoxynucleoside analogs. Biochem Pharmacol 1991; 42: R5-8
102. LeLacher SF, Simon GI. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538-9
103. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995; 345: 460-1
104. Gazzard BG, Moyle GJ. The role of didanosine in the management of HIV-1 infection. Antiviral Therapy 1997; 2 (3): 135-47
105. Sahai J. Risks and synergies from drug interactions. AIDS 1996; 10 Suppl. 1: S21-5
106. Adkins JC, Peters DH, Faulds D. Zalcitabine: an update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997 Jun; 53 (6): 1054-80
107. Ferry JJ, Herman BD, Cox SR, et al. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic drug-drug interaction study in healthy adult volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
108. Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic interaction between saquinavir and delavirdine in healthy volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22-26; Washington, DC
109. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft gel capsule exposure in HIV patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22-26; Washington, DC
110. Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct; 52 (4): 541-6
111. Cato A, Cavanaugh J, Shi H, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract no. Mo.B.1199]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
112. Bertz R, Cao G, Cavanaugh J, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstract no. Mo.B.1201]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
113. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinylestradiol in healthy female volunteers [abstract no. Mo.B.1198]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
114. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract no. Mo.B.1200]. XIth International Conference on AIDS; 1996 Jul 7-12: Vancouver
115. Yven G, Anderson R, Daniels R, et al. Investigation of nelfinavir mesylate pharmacokinetic interactions with indinavir and ritonavir [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
116. McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1947 Jan 22-26: Washington, DC
117. Kerr B, Yven CJ, Daniels R, et al. Strategic approach to nelfinavir mesylate drug interactions involving CYP3A metabolism [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
118. Back DJ, Haggard PG, Veal GJ, et al. Intracellular phosphorylation interactions between nucleoside analogues [abstract no. 41]. 5th European Conference on Clinical Aspects and Treatment of HIV Infection; 1995: Copenhagen
119. Ruiz L, Romeu J, Martainez-Picado J, et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV/3TC) combination therapy in patients previously treated with ZDV/ ddC. AIDS 1996; 10: F61-6
120. Stretcher BN, Pesce AJ, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease: progression and drug-toxicity. AIDS 1944; 8: 763-9
121. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retrovirol 1994; 8: 907-12
122. Merrill DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996; 173: 355-64
123. Merrill DP, Manion DJ, Chou T-C, et al. Protease inhibitor combination regimens against HIV-1 in vitro. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
124. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 23-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269: 12633-8
125. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype tor rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8
126. Richman DD, Bozette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-74
127. Schellekens PTA, Koot M, Roos MTL, et al. Immunologic and virologic markers determining progression to AIDS. J Acquir Immune Defic Syndr 1995; 10 Suppl. 2: S62-6
128. Delforge M-L, Liesnard C, Debaisieux L, et al. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995; 9: 89-90
129. Moyle G. Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996; 5: 155-67
130. Epstein LG, Kuiken C, Blumberg BM, et al. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology 1991; 180: 583-90
131. Ball JK, Holmes EC, Whitwell H, et al. Genomic variation of human immunodeficiency virus type-1 (HIV-1): molecular analysis of HIV-1 in sequential blood samples and various organs obtained at autopsy. J Gen Virol 1994; 75: 867-79
132. Haggerty S, Stevenson M. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol 1991; 4: 123-31
133. Wildemann B, Haas J, Ehrhart K, et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 1993; 43: 2659-63
134. Portegies P. AIDS dementia complex: a review. J Acquir Immune Defic Syndr 1994; 7 Suppl. 2: S38-49
135. Di Stephano M, Norkrans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in brain [letter]. Lancet 1993; 342: 865
136. Foudraine N, de Wolf F, Hoetelmans R, et al. CSF and serum HIV-RNA during AZT/3TC and d4T/3TC treatment. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
137. Collier AC, Marra C, Coombs RW, et al. Cerebiospinal fluid (CSF) indinavir (IDV) and HIV RNA levels in patients on chronic indinavir therapy [abstract no. 286]. Infectious Diseases Society of America Annual Meeting; 13-16 Sep 1997: San Francisco
138. Moyle GJ, Sadler M, Buss N, et al. Correlation between plasma and CSF viral load in patients on saquinavir containing regimens: pharmacokinetics (PK) of saquinavir at steady state in CSF and plasma [abstract no. 249]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11-15: Hamburg
139. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996 Aug; 52 (2): 168-85
140. Moyle G. Influence of emergence of viral resistance on HIV treatment choice. Int J STD AIDS 1995; 6: 225-6
141. Moyle GJ. Current knowledge of HIV-1 reverse transcriptase (RT) mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997; 40: 765-77
142. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-8
143. Tremblay M, Rooke R, Wainberg MA. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity. AIDS 1992; 6: 1445-9
144. Caliendo A, Savara A, An D. Zidovudine-resistance mutations increase replication in drug-free PBMC stimulated after infection [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 2-3
145. Mayers DL, Japour AJ, Arduino J-M, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob Agents Chemother 1994; 38: 307-14
146. Rooke R, Parniak MA, Tremblay M, et al. Biological comparisons of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother 1991; 35: 988-91
147. Dianzani F, Antonelli G, Turriziani O, et al. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994; 10: 1471-8
148. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121: 263-8
149. Gu Z, Gao Q, Parniak MA, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992; 66: 7128-35
150. Gao Q, Gu ZX, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390-2
151. Lin HJ, Myers LE, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994; 170: 553-62
152. Fitzgibbon JE, Howell RM, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which caused decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992; 36: 153-7
153. Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS 1997; 11:271-9
154. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71
155. Jacobsen H, Hanggi M, Ou M, et al. In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996; 173: 1379-87
156. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterisation of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir [abstract no. 29]. 5th International Workshop on HIV Drug Resistance: 1996 Jul 3-6: Whistler, British Columbia, Canada
157. Tisdale M, Myers R, Najera I, et al. Analysis of resistant interactions with 141W94 (VX-478) and other protease inhibitors. 5th International Workshop on HIV Drug Resistance; 1996 Jul 3-6: Whistler, British Columbia, Canada
158. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-13
159. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mother to infants. Science 1992; 255: 1134-7
160. Zhang L, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67: 3345-56
161. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993; 261: 1179-81
162. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-1
163. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-8
164. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16
165. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201-8
166. Hogervorst E, Jurriaans S, deWolf F, et al. Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995; 171: 811-21
167. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-9
168. Luque F, Caruz A, Pineda JA, et al. Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994; 169: 267-73
169. Yerly S, Kaiser L, Baumberger C, et al. Early and prolonged decrease of viraemia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr 1995; 8: 358-64
170. Yerly S, Kaiser L, Mermillod B, et al. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995; 9: 159-63